ImmunoVaccine Technologies Inc. (IVT) appoints Dr. Michel Klein and Dr. Walter Storkus, international experts in immunology, to its scientific advisory board.
Dr. Michel Klein is the deputy CEO at Etna Biotech s.r.l. and serves as an expert consultant to the EU as a member of the Partnership Board for European and Developing Countries Clinical Trials Partnership (EDCTP). He has authored more than 200 scientific publications and secured 500 patents in immunology, molecular biology and vaccinology. He is also a knight in the order of the French Legion d’Honneur. Dr. Klein received an MD from the Faculty of Medicine of Paris and a diploma in immunology from Institut Pasteur in 1969. Dr. Klein previously held the positions of professor of immunology at the University of Toronto and of vice president research at Aventis Pasteur.
“As a clinician and a researcher, I look forward to providing direction as IVT breaks new ground in the fields of cancer treatment and immunization,” remarked Dr. Klein.
Dr. Walter Storkus currently is a professor (tenure) with the Departments of Dermatology and Immunology at the University of Pittsburgh. His past positions include head of research – division of surgical oncology, department of surgery and professor (tenure) for the departments of surgery and pathology, as well as the departments of surgery, dermatology and immunology at the University of Pittsburgh. Dr. Storkus has authored more than 170 scientific publications and has memberships in numerous professional and societies throughout the United States. Dr. Storkus received his PhD in microbiology and immunology from Duke University in 1986.
“I have devoted my life to cancer research and am proud to lend guidance to IVT’s innovative research in improving existing vaccines and developing new vaccines based on the VacciMax® platform,” said Dr. Storkus.
“It’s an exciting pre-clinical time for IVT. The timing of the appointment of these new members is perfect,” said Dr. W. Martin Kast, chair of the scientific advisory board. “Drs Klein and Storkus bring the drive and the enthusiasm that is needed to guide our research and business growth,” continued Kast.
“We are delighted to have Dr. Klein and Dr. Storkus on our scientific advisory board, as their expertise will provide invaluable contribution to our continued development in pioneering the use of our patented vaccine platform,” commented Dr. Randal Chase, president and CEO of IVT.
IVT is a vaccine enhancement company focused on the commercialization of its patented VacciMax® platform. VacciMax® is a novel technology capable of improving existing vaccines or aiding the development of new vaccines in human health and animal health applications with potential for both preventative and therapeutic use. The potential market applications and medical benefits of VacciMax® are broad, and are currently being applied to cervical and melanoma cancers and prevention therapies as well as influenza and other infectious diseases.
For more information, please contact:
Communications and Investor Relations
T 902.423.6610 x 315
Chief Operating Officer
Halifax, Nova Scotia, May 31, 2007